[Clinical Features and Prognosis of Patients with CD5⁺ Diffuse Large B-Cell Lymphoma]

To analyze the clinical characteristics and prognosis of patients with CD5⁺ diffuse large B-cell lymphoma (DLBCL).

The clinical data of 161 newly treated DLBCL patients in Gansu Provincial Hospital from January 2013 to January 2020 were retrospectively analyzed. According to CD5 expression, the patients were divided into CD5⁺ group and CD5^- group. The clinical characteristics and prognosis of the two groups were statistically analyzed.

The median age of patients in CD5⁺ group was 62 years, which was higher than 56 years in CD5^- group (P =0.048). The proportion of women in CD5⁺ group was 62.96%, which was significantly higher than 41.79% in CD5^- group (P =0.043). The proportion of patients with IPI score > 2 in CD5⁺ group was 62.96%, which was higher than 40.30% in CD5^- group (P =0.031). Survival analysis showed that the median overall survival and progression-free survival time of patients in CD5⁺ group were 27(3-77) and 31(3-76) months, respectively, which were both shorter than 30(5-84) and 32.5(4-83) months in CD5^- group (P =0.047, P =0.026). Univariate analysis showed that advanced age, positive CD5 expression, triple or double hit at initial diagnosis, high IPI score and no use of rituximab during chemotherapy were risk factors for the prognosis of DLBCL patients. Further Cox multivariate regression analysis showed that these factors were also independent risk factors except for advanced age.

CD5⁺ DLBCL patients have a worse prognosis than CD5^- DLBCL patients. Such patients are more common in females, with advanced age and high IPI score, which is a special subtype of DLBCL.